The estimated Net Worth of J Jay Lobell is at least $3.03 Milion dollars as of 10 February 2023. Mr. Lobell owns over 299,401 units of Fortress Biotech Inc stock worth over $2,878,306 and over the last 9 years he sold FBIO stock worth over $0. In addition, he makes $153,500 as Independent Director at Fortress Biotech Inc.
Sign up
Mr. Lobell FBIO stock SEC Form 4 insiders trading
J has made over 1 trades of the Fortress Biotech Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 299,401 units of FBIO stock worth $251,497 on 10 February 2023.
The largest trade he's ever made was buying 299,401 units of Fortress Biotech Inc stock on 10 February 2023 worth over $251,497. On average, J trades about 19,960 units every 0 days since 2016. As of 10 February 2023 he still owns at least 1,635,401 units of Fortress Biotech Inc stock.
You can see the complete history of Mr. Lobell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Jay Lobell biography
J. Jay Lobell J.D. serves as Independent Director of the Company. Mr. Lobell has served as a member of the Board of Directors since June 2006. Mr. Lobell is CEO and Co-Founder of GMF Capital, LLC which he co-founded in January 2016, and is a Senior Consultant and serves on the board of directors of Meridian Capital Group, LLC, a commercial real estate mortgage company, which he joined in January 2010. Mr. Lobell was also a founder of Beech Street Capital, LLC, a real estate lending company, serving as its Vice Chairman from December 2009 until the company’s sale to Capital One Financial Corporation in November 2013. From January 2005 to December 2009, Mr. Lobell served as President and Chief Operating Officer of Paramount Biosciences, LLC, or PBS, a private biotechnology investment and development company. In that capacity, he had substantial responsibility for the assembly and oversight of companies PBS founded and incubated, including the Company and Asphelia Pharmaceuticals, Inc. Mr. Lobell currently serves on the board of directors of Sava Senior Care and Tender Touch Rehabilitation Services, both private companies. He previously served on the board of directors of NovaDel Pharma Inc., Innovive Pharmaceuticals, Inc., and Chem Rx Corporation (a private company). Mr. Lobell was a partner in the law firm Covington & Burling LLP from October 1996 through January 2005, where he advised companies and individuals as a member of the firm’s securities litigation and white collar defense practice group. Mr. Lobell received his B.A. (summa cum laude, Phi Beta Kappa) from The City University of New York and his J.D. from Yale Law School, where he was senior editor of The Yale Law Journal. Based on Mr. Lobell’s biotechnology, legal and financial experience, as well as his in-depth understanding of drug commercialization and corporate governance, the Board of Directors believes that Mr. Lobell has the appropriate set of skills to serve as a member of the Board in light of the Company’s business and structure.
What is the salary of J Lobell?
As the Independent Director of Fortress Biotech Inc, the total compensation of J Lobell at Fortress Biotech Inc is $153,500. There are 8 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
How old is J Lobell?
J Lobell is 57, he's been the Independent Director of Fortress Biotech Inc since 2006. There are 8 older and 3 younger executives at Fortress Biotech Inc. The oldest executive at Fortress Biotech Inc is Malcolm Hoenlein, 76, who is the Independent Director.
What's J Lobell's mailing address?
J's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Insiders trading at Fortress Biotech Inc
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss oraz George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
What does Fortress Biotech Inc do?
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
What does Fortress Biotech Inc's logo look like?
Complete history of Mr. Lobell stock trades at Fortress Biotech Inc i Fortress Biotech Inc
Fortress Biotech Inc executives and stock owners
Fortress Biotech Inc executives and other stock owners filed with the SEC include:
-
Robyn Hunter,
Chief Financial Officer, Treasurer, Secretary -
Michael Weiss,
Executive Vice Chairman - Strategic Development, Director -
Lindsay Rosenwald,
Executive Chairman of the Board, President, Chief Executive Officer -
Robyn M. Hunter,
CFO, Treasurer & Corp. Sec. -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman, Pres & CEO -
Michael S. Weiss Esq.,
Vice Chairman & Exec. Vice Chairman of Strategic Devel. -
George Avgerinos,
Senior Vice President - Biologics Operations -
Eric Rowinsky,
Co-Vice Chairman and Director -
J. Jay Lobell,
Independent Director -
Dov Klein,
Independent Director -
Jimmie Harvey,
Independent Director -
Malcolm Hoenlein,
Independent Director -
Kevin Lorenz,
Independent Director -
Jaclyn Jaffe,
IR Contact Officer -
Dr. Thomas F. Schaible,
Project Leader of Inflammatory Bowel Disease -
David Jin,
Chief Financial Officer -
Lucy Lu,
Director